Search research articles
Contact Us
Filters
Showing results (41-50 of 120) with videos related to
Page
of 12
Sort By:
Plos One
|
December 20, 2012
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response
Hugo Geerts, Athan Spiros, Patrick Roberts, et al.
Journal of Affective Disorders
|
March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
Ibrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Current Medical Research and Opinion
|
September 22, 2019
Descriptive analysis of the economic burden of treatment resistance in a major depressive episode
Qian Cai, John J Sheehan, Bingcao Wu, et al.
Annals of General Psychiatry
|
July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Michael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
International Clinical Psychopharmacology
|
July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
Bennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
Annals of General Psychiatry
|
April 13, 2011
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
Larry Alphs, Cynthia A Bossie, Jennifer K Sliwa, et al.
International Clinical Psychopharmacology
|
March 3, 2015
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
Erica A Voss, Patrick B Ryan, Paul E Stang, et al.
Schizophrenia Research
|
October 1, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis
Steven G Potkin, Phillip Phiri, Armin Szegedi, et al.
Plos One
|
August 9, 2019
An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression
Bingcao Wu, Qian Cai, John J Sheehan, et al.
CNS Drugs
|
September 23, 2011
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
Mahesh N Samtani, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 120) with videos related to
Sort By:
Page
of 12
Plos One
|
December 20, 2012
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response
Hugo Geerts, Athan Spiros, Patrick Roberts, et al.
Journal of Affective Disorders
|
March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression
Ibrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Current Medical Research and Opinion
|
September 22, 2019
Descriptive analysis of the economic burden of treatment resistance in a major depressive episode
Qian Cai, John J Sheehan, Bingcao Wu, et al.
Annals of General Psychiatry
|
July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Michael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
International Clinical Psychopharmacology
|
July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
Bennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
Annals of General Psychiatry
|
April 13, 2011
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
Larry Alphs, Cynthia A Bossie, Jennifer K Sliwa, et al.
International Clinical Psychopharmacology
|
March 3, 2015
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
Erica A Voss, Patrick B Ryan, Paul E Stang, et al.
Schizophrenia Research
|
October 1, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis
Steven G Potkin, Phillip Phiri, Armin Szegedi, et al.
Plos One
|
August 9, 2019
An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression
Bingcao Wu, Qian Cai, John J Sheehan, et al.
CNS Drugs
|
September 23, 2011
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
Mahesh N Samtani, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
Page
of 12